



## **New CEO at Respiratorius AB**

Jörgen Gustafsson has been appointed new CEO at Respiratorius AB (publ) from December 8 2008.

Jörgen comes from a recent position as Evaluation Director at AstraZeneca's Strategic Planning Business Development Unit in which he had the global responsibility for evaluations of external business opportunities in the field of Respiratory & Inflammation.

In his position as Evaluation Director Jörgen has represented AstraZeneca as global business contact within the therapeutic area Respiratory & Inflammation. This has involved extensive partnering activities at external meetings and in conferences in order to seek and establish relations with Small /Mid-size/Big Pharma aiming to find new business opportunities. In this capacity he has evaluated hundreds of external pharmaceutical and biotech projects in the field of COPD and Asthma and has managed multiple global evaluation teams within AstraZeneca in Respiratory Diseases.

Jörgen has earlier been responsible for scientific collaborations and alliances within the therapeutic area Respiratory & Inflammation. In this capacity he was responsible for the negotiation and transaction of over 150 agreements with third parties in US, Japan and Europe. Prior to working in business development his carrier involved research as a medicinal chemist involving laboratory research, project management and line management. Jörgen has a PhD in organic chemistry and has prior to working at AstraZeneca held several research positions at Pharmacia, Pharmacia & Upjohn and Active Biotech.

"Respiratorius will now focus on establishing one or more business collaborations with Mid-size /Big Pharma. Jörgen brings to Respiratorius a unique experience and insight from the licensing area regarding drug candidates for treatment of Respiratory Diseases. He also brings knowledge and insight around global strategies in Big Pharma regarding research and development for Respiratory Diseases. His large network of established personal key contacts at Mid-size /Big Pharma around the world will be a great value to Respiratorius. In addition, Jörgen also has a broad experience in working with academic institutions all over the world including key opinion leaders in the field of Respiratory Diseases says Christer Fåhræus, Chairman of the board in Respiratorius.

"Entering the position as CEO at Respiratorius is very exciting. I have with great interest studied Respiratorius portfolio and its business plan. I am certain that Respiratorius unique compounds will generate great interest from major pharmaceutical players. In my daily work as Evaluation Director I have encountered and evaluated a number of drug candidates so I have good understanding of what Big Pharma is looking for. This knowledge will be an asset in my work as CEO and in the marketing of Respiratorius drug candidates says Jörgen Gustafsson.

The Board would like to express their gratitude to Karin Wehlin for her much appreciated services with the company and wished her all the best in her new role as Marketing Director for Wild Wonders of Europe Ltd.

For further questions please contact:

Christer Fåhræus, Chairman of the Board, Respiratorius AB +46 705 60 90 00  
[Christer.fahraeus@respiratorius.com](mailto:Christer.fahraeus@respiratorius.com)  
[www.respiratorius.com](http://www.respiratorius.com)

*Respiratorius develops new effective pharmaceuticals against the diseases Chronic Obstructive Pulmonary Disease (COPD) and severe asthma. The company's unique approach is focused on a new class of patent protected pharmaceutical substances, that compared to existing therapies have a superior ability to relax the small airways. The substances, which make use of an entirely new mechanism of action, are developed using the company's world-leading, proprietary force measurement equipment.*